FLORONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLORONE (FLORONE).
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
| Metabolism | Primarily hepatic via CYP3A4-mediated oxidation; undergoes glucuronidation and sulfation; excreted renally. |
| Excretion | Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder). |
| Half-life | Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Apparent volume of distribution approximately 0.5-1.0 L/kg; indicates distribution into total body water with some tissue binding. |
| Bioavailability | Topical: negligible systemic absorption (less than 5% through intact skin); ocular: minimal systemic absorption; oral: not available; parenteral: not applicable. |
| Onset of Action | Topical: rapid within minutes (vasoconstriction); systemic: not applicable for routine use; ocular: within 1-2 hours for anti-inflammatory effect. |
| Duration of Action | Topical vasoconstriction: 2-4 hours; anti-inflammatory effects persist for 24-48 hours after single dose; clinical note: frequency of application every 6-12 hours for dermatoses. |
| Molecular Weight | 494.5 Da |
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption is negligible. |
| Pediatric use | Children ≥2 years: Apply a thin layer once or twice daily; use the least potent formulation and limit treatment duration. Children <2 years: Not recommended due to risk of systemic toxicity. |
| Geriatric use | Use with caution: apply minimal amount for shortest duration due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Topical corticosteroids like FLORONE (diflorasone diacetate) should be used during the first trimester only if the potential benefit justifies the potential risk to the fetus. Studies indicate an increased risk of orofacial clefts with systemic use, but topical application minimizes systemic absorption. However, prolonged or widespread use should be avoided. |
| 2nd trimester | Use during the second trimester with caution; same risks as first trimester. Limit to short-term, small areas. Avoid high potency formulations on large areas or for extended periods. |
| 3rd trimester | Use in third trimester may be associated with fetal growth restriction and adrenal suppression. Avoid use near term due to potential for neonatal hypothalamic-pituitary-adrenal axis suppression. Only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for FLORONE (FLORONE).
| Placental transfer | Topical corticosteroids, including diflorasone diacetate, can cross the placenta. The degree of transfer depends on the extent of systemic absorption, which is influenced by application site, skin integrity, and duration of use. After systemic absorption, placental transfer occurs via passive diffusion. High potency and occlusive use increase systemic levels and therefore placental transfer. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any component of the formulationUntreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella)
| Precautions | Topical corticosteroids may cause HPA axis suppression, especially with prolonged use, large surface area, or occlusive dressings., Systemic absorption may produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Use with caution in pediatric patients; may be more susceptible to systemic toxicity., May cause local adverse reactions including atrophy, striae, telangiectasias, and contact dermatitis., Use in skin infections may mask or worsen infection; appropriate antimicrobial therapy should be used if infection is present. |
| Food/Dietary | No specific food interactions are documented. However, concomitant use of grapefruit juice may affect CYP3A4 metabolism of systemic corticosteroids; while topical application minimizes systemic absorption, caution may still be warranted. |
Loading safety data…
| Breastfeeding | Topical corticosteroids are excreted into breast milk in negligible amounts after maternal topical application, but systemic absorption can occur with prolonged or widespread use. Use the lowest potency for the shortest duration. Avoid application to the breast area to prevent infant ingestion. Monitor infant for signs of adrenal suppression (e.g., poor feeding, growth delay). |
| Lactation Rating | L2 (Safer; limited data suggest minimal risk) |
| Teratogenic Risk | FLORONE (diflorasone diacetate) is a topical corticosteroid. Systemic absorption is minimal with topical use, but if significant absorption occurs, corticosteroids may cause fetal harm. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. First trimester: Use only if potential benefit justifies risk to fetus. Second and third trimesters: Prolonged use may lead to fetal adrenal suppression. Avoid high potency formulations over large areas. |
| Fetal Monitoring | Monitor maternal adrenal function with prolonged use or large surface area application. Assess fetal growth via ultrasound if prolonged high-dose use. Monitor for signs of fetal adrenal suppression (e.g., poor feeding, hypoglycemia) in neonates after maternal use. |
| Fertility Effects | No data on human fertility effects. Animal studies with corticosteroids have shown impaired fertility at high doses. Clinically significant effects are unlikely with topical use due to minimal systemic absorption. |
| Clinical Pearls | FLORONE (diflorasone diacetate) is a high-potency topical corticosteroid. Use with caution on the face, intertriginous areas, and in children due to increased systemic absorption. Occlusive dressings can enhance absorption and efficacy but also increase risk of adverse effects. Do not use for longer than 2 consecutive weeks unless directed. Monitor for HPA axis suppression with prolonged use. |
| Patient Advice | Apply a thin layer to affected areas only; avoid contact with eyes and mucous membranes. · Do not cover with bandages or dressings unless instructed by your doctor. · Use only as directed; do not use for longer than prescribed. · Wash hands after application unless treating hands. · Inform your doctor if you experience skin thinning, burning, or signs of infection. |